The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans.
Author(s): Newton TF, De La Garza R 2nd, Grasing K
Affiliation(s): Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, and the Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. firstname.lastname@example.org
Publication date & source: 2010-08-30, Psychiatry Res., 179(1):96-100. Epub 2010 May 20.
Publication type: Randomized Controlled Trial; Research Support, N.I.H., Extramural
A variety of medications have been assessed for their potential efficacy for the treatment of methamphetamine dependence. We conducted this study in an attempt to evaluate the potential of a novel class of medications, angiotensin-converting enzyme inhibitors, as treatments for methamphetamine dependence. All participants met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, third revision (DSM-IV-TR) criteria for methamphetamine abuse or dependence and were not seeking treatment at the time of study entry. The study was conducted using a double-blind design. Subjects received a baseline series of intravenous (IV) doses of methamphetamine (15 mg and 30 mg) and placebo. Subjects received a second identical series of methamphetamine doses 3 and 5 days after initiation of once-daily oral placebo or perindopril treatment. The dose of perindopril was 2 mg, 4mg, or 8 mg administered in the morning. Perindopril treatment was tolerated well. There were no main effects of perindopril on methamphetamine-induced changes in cardiovascular or subjective effects. There were significant perindoprilmethamphetamine interactions for diastolic blood pressure and for ratings of "Any Drug Effect", indicating inverted U dose-effect functions for these indices. Copyright (c) 2009 Elsevier Ltd. All rights reserved.